Meta-analysis of the significance of asymptomatic bacteriuria in diabetes mellitus
We were able to show that the prevalence of ASB is higher in all patients with diabetes mellitus as compared to controls. We also found that diabetics with ASB had more often albuminuria and symptomatic urinary tract infections (Diabetes Care)
Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes
Contrary to popular perception, a short course of IIT resulted in significant improvements in QOL and treatment satisfaction, demonstrating the patient acceptability of early insulin therapy (Journal of Evaluation in Clinical Practice)
Continuous Glucose Monitoring Consensus Statement Released by AACE
A comprehensive consensus statement on continuous glucose monitoring from the American Association of Clinical Endocrinologists (AACE)
Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress
Our data demonstrate loss of enteric neurons in the colon due to increased oxidative stress and apoptosis which may cause the motility disturbances seen in human diabetes. Antioxidants may be of therapeutic value for preventing motility disorders in diabetes (Neurogastroenterology & Motility)
Proinsulin Cysteine Residues Impose Dominant-Negative Inhibition on Wild-Type Proinsulin Transport
We conclude that the molecular pathogenesis of MIDY is initiated by perturbation of the disulfide-coupled folding pathway of wild-type proinsulin (PLoS ONE)
The temporal relationship between glucose-corrected serum sodium and neurological status in severe diabetic ketoacidosis
Glucose-corrected serum sodium may prove a useful early warning for the development of cerebral oedema in DKA (Archives of Disease in Childhood)
Enhanced Excretion of Vitamin D Binding Protein in Type 1 Diabetes: A Role in Vitamin D Deficiency?
These findings suggest that, theoretically, exaggerated urinary loss of VDBP in T1D, particularly in persons with albuminuria, could contribute mechanistically to vitamin D deficiency in this disease (Journal of Clinical Endocrinology & Metabolism)
Do social inequalities exist in terms of the prevention, diagnosis, treatment, control and monitoring of diabetes? A systematic review
This review shows that even in countries with a significant level of economic development and which have universal healthcare systems in place which endeavour to provide medical care to the entire population, socioeconomic and ethnic inequalities can be identified in the provision of health-care to DM sufferers (Health & Social Care in the Community)
Treatment with antipsychotics and the risk of diabetes in clinical practice.
In clinical practice, treatment with first- and second-generation antipsychotics is associated with an increased risk of developing incident diabetes with large differences between individual drugs. The risk increases with the duration of treatment and with polypharmacy of antipsychotic drugs (PubMed – British Journal of Psychiatry)
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 diabetes
Spherix Incorporated announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes (Forbes)
Glycaemic control with liraglutide: the phase 3 trial programme
Overall, the phase 3 clinical trial programme has demonstrated that liraglutide is a well-tolerated and effective therapy for type 2 diabetes that can offer effective glycaemic control and produce sustained reductions in HbA1c, FPG and PPG levels for patients throughout the continuum of care (International Journal of Clinical Practice)
Financial conflicts of interest linked to author’s views on MI risk with rosiglitazone
This MeReC monthly article (on page 3 of the newsletter) discusses a systematic review which found a link between the authors’ financial conflicts of interests with pharmaceutical companies and their views on the association of rosiglitazone with increased risk of MI (NPS, NHS)